Brief: Compugen Announces Updated Data From Phase 1 Study Of Com701
08/06/2021 12:31
June 8 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN ANNOUNCES UPDATED DATA FROM PHASE 1 STUDY OF
COM701,
FIRST- IN-CLASS ANTI-PVRIG, AT THE ASCO 2021 ANNUAL MEETING
Source text for Eikon: ID:nPn61HNyZa
Further company coverage: CGEN.TA
((reuters.briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025